SCHEDULE 13G/A: Major Shareholder Dr. Hans-Peter Wild Consolidates Ownership in ADC Therapeutics SA Following Executive's Departure

An amended Schedule 13G filing reveals Dr. Hans-Peter Wild has consolidated his beneficial ownership in ADC Therapeutics SA to 9.61% following the transfer of interests from former board member Thomas Pfisterer.

Summary

• HPWH TH AG, Dr. Hans-Peter Wild, and Thomas Pfisterer filed an amended Schedule 13G regarding their beneficial ownership in ADC Therapeutics SA.
• As of May 13, 2025, ADC Therapeutics SA had 101,811,051 ordinary shares issued and outstanding.
• HPWH TH AG beneficially owns 8,670,588 common shares, representing 8.52% of the class, with sole voting and dispositive power.
• Dr. Hans-Peter Wild beneficially owns 9,788,944 common shares, representing 9.61% of the class, with sole voting and dispositive power. This includes shares held directly and indirectly.
• Thomas Pfisterer beneficially owns 173,899 common shares, representing 0.17% of the class, with sole voting and dispositive power.
• Mr. Pfisterer has transferred all his direct or indirect interests in HPWH MH AG and HPWH TH AG to Dr. Hans-Peter Wild.
• Mr. Pfisterer has also stepped down as a Board Member of HPWH TH AG.
• Previously, Mr. Pfisterer may have been deemed to have shared voting and investment power with respect to shares held by HPWH due to a stockholders' agreement and joint indirect equity interest, but he has disclaimed such power.

Sentiment

Score: 5

Explanation: The document is a factual report on beneficial ownership changes, with no explicit positive or negative financial or operational news. The consolidation of ownership by a major shareholder is a neutral event in itself, though it could be interpreted positively by some as a sign of commitment.

Positives

• Consolidation of ownership by a key shareholder (Dr. Hans-Peter Wild) may indicate strong long-term commitment and simplified ownership structure.

Negatives

• The departure of Thomas Pfisterer from the HPWH TH AG Board and the transfer of his interests could signal a change in the investment group's strategy or internal dynamics, though the document does not elaborate on the reasons beyond him stepping down.

Future Outlook

NA

Management Comments

• "Dr. Wild is the Chairman of HPWH and HPW Holding."
• "Thomas Pfisterer was a Board Member of HPWH and an investment manager but stepped down from this position."
• "Mr. Pfisterer has disclaimed such power [shared voting and investment power], has left all of such companies, and has transferred all of his direct or indirect interests in MH and HPWH to Dr. Wild."

Industry Context

This filing is specific to a change in beneficial ownership for ADC Therapeutics SA. It does not provide broader industry context or trends.

Management Changes

Corporate Governance

Related Party Transactions

• The transfer of all direct and indirect interests in HPWH MH AG and HPWH TH AG from Thomas Pfisterer to Dr. Hans-Peter Wild.

Stakeholder Impact

• Shareholders: The consolidation of ownership by Dr. Hans-Peter Wild may provide clarity on the ultimate control of a significant block of shares. It could be viewed as a vote of confidence or a concentration of power.
• Management: The change in the ownership structure of a major shareholder group might influence future interactions or strategic alignment, though no direct impact on ADC Therapeutics SA's management is stated.

Key Dates

Keywords

ADC Therapeutics SA, Schedule 13G, beneficial ownership, Dr. Hans-Peter Wild, HPWH TH AG, Thomas Pfisterer, common shares, shareholder, ownership consolidation, SEC filing